SCHEMBL12593153

SCHEMBL12593153

CC(=O)/C=C/c1ccc(O)c(CO)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.67
PTGS1 P23219 2/20 0.67
MMP2 P08253 4/20 0.62
MMP9 P14780 4/20 0.62
NFKB1 P19838 3/20 0.62
MMP8 P22894 2/20 0.62
APP P05067 4/20 0.58
AKR1B1 P15121 3/20 0.56
AKR1B10 O60218 2/20 0.56
AKR1C3 P42330 1/20 0.56
MMP13 P45452 2/20 0.54
PKM P14618 2/20 0.53
PTPN1 P18031 3/20 0.48
FDPS P14324 1/20 0.47
HSD17B10 Q99714 4/20 0.46
KDM4E B2RXH2 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
CYP2C9 P11712 3/20 0.46
TSHR P16473 3/20 0.46
TTR P02766 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034413 0.87 IAPP (0.67) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL11928834 0.86 IAPP (0.56) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL29395741 0.85 AKR1C3 (0.66) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL13663908 0.85 MMP9 (0.76) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL2601403 0.85 AKR1C3 (0.66) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL12555874 0.85 AKR1C3 (0.66) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL14802240 0.84 MMP9 (0.71) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL12599489 0.84 MMP9 (0.71) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL15298278 0.84 MMP9 (0.64) IAPPPTGS1MMP2MMP9NFKB1
SCHEMBL15042796 0.83 MMP2 (0.55) IAPPPTGS1MMP2MMP9NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364171-A1 SENSORY MODIFIER COMPOUNDS CARGILL, INCORPORATED (US) 2023-11-16 US disclosed
US-20230364069-A1 METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) 2023-11-16 US disclosed
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-11701400-B2 Steviol glycoside compositions with reduced surface tension CARGILL, INCORPORATED (US) 2023-07-18 US disclosed
US-11654120-B2 Composition for treating skin conditions OLLIE'S HEALTH, LLC (US) 2023-05-23 US disclosed
US-20230127708-A1 GASIFIED SOLUTIONS WITH IMPROVED SENSORY PROPERTIES CARGILL, INCORPORATED (US) 2023-04-27 US disclosed
US-20230126688-A1 Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by Antioxidants for Parenteral Administration AMGEN INC. 2023-04-27 US disclosed
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2023-04-27 US disclosed
US-20180078535-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2018-03-22 US disclosed
US-9907786-B2 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof IONS PHARMACEUTICAL S.À R.L. (LU) 2018-03-06 US disclosed
US-20150208705-A1 ANTHOCYANIN COLOURING COMPOSITION NESTEC S.A. (CH) 2015-07-30 US disclosed
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES STC.UNM 2015-01-08 US disclosed
US-20140294859-A1 AQUEOUS FORMULATION OF ERYTHROPOIESIS STIMULATING PROTEIN STABILISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION AMGEN INC. (US) 2014-10-02 US disclosed
US-20130237609-A1 CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS EDGAR KEVIN J (US) 2013-09-12 US disclosed
US-20130157986-A1 NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE INVASC THERAPEUTICS, INC. (US) 2013-06-20 US disclosed
US-20110123646-A1 Extracts Obtained from Cell Line Cultures from Plants Belonging to the Oleaceae Family (e.g. Syringa Vulgaris), Their Preparation and Use I.R.B. ISTITUTO DI RICERCHE BIOTECNOLOGICHE S.R.L. (IT) 2011-05-26 US disclosed
US-20110123646-A1 Extracts Obtained from Cell Line Cultures from Plants Belonging to the Oleaceae Family (e.g. Syringa Vulgaris), Their Preparation and Use I.R.B. ISTITUTO DI RICERCHE BIOTECNOLOGICHE S.R.L. (IT) 2011-05-26 US disclosed
US-7718199-B2 Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use I.R.B. ISTITUTO DI RICERCHE BIOTECNOLOGICHE S.R.L. (IT) 2010-05-18 US disclosed
US-20070015262-A1 Extracts from Ajuga reptans cell lines, their preparation and use I.R.B. ISTITUTO DI RICERCHE BIOTECNOLOGICHE S.R.L. (IT) 2007-01-18 US disclosed
US-20070004011-A1 Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use I.R.B. ISTITUTO DI RICERCHE BIOTECNOLOGICHE S.R.I. (IT) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237609-A1 CELLULOSE DERIVATIVES FOR ENHANCING BIOAVAILABILITY OF FLAVONOIDS KEAP1, NQO1, ABCG2 IAPP 295/4885PTGS1 1696/4885MMP2 1679/4885
US-20140294859-A1 AQUEOUS FORMULATION OF ERYTHROPOIESIS STIMULATING PROTEIN STABILISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION EPOR, TTPA, ALB IAPP 751/4885PTGS1 1753/4885MMP2 3641/4885
US-20070015262-A1 Extracts from Ajuga reptans cell lines, their preparation and use TTPA, FABP4, ACOX3 IAPP 2590/4885PTGS1 345/4885MMP2 510/4885
US-11701400-B2 Steviol glycoside compositions with reduced surface tension STT3A, SIGLEC7, STT3B IAPP 3432/4885PTGS1 675/4885MMP2 2237/4885
US-20180078535-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT IAPP 1777/4885PTGS1 3044/4885MMP2 1432/4885
US-20070004011-A1 Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use CAT, CUTA, VAPA IAPP 2810/4885PTGS1 807/4885MMP2 87/4885
US-20230126688-A1 Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by Antioxidants for Parenteral Administration EPOR, TTPA, ALB IAPP 751/4885PTGS1 1753/4885MMP2 3641/4885
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF BAD, BAX, PDCD4 IAPP 3164/4885PTGS1 2332/4885MMP2 1190/4885
US-20130157986-A1 NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE REN, PCSK9, COMT IAPP 350/4885PTGS1 131/4885MMP2 111/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 IAPP 214/4885PTGS1 1023/4885MMP2 4044/4885
US-20110123646-A1 Extracts Obtained from Cell Line Cultures from Plants Belonging to the Oleaceae Family (e.g. Syringa Vulgaris), Their Preparation and Use CAT, CUTA, VAPA IAPP 2810/4885PTGS1 807/4885MMP2 87/4885
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES FABP2, GLS2, FABP1 IAPP 336/4885PTGS1 153/4885MMP2 399/4885
US-11654120-B2 Composition for treating skin conditions CUTA, DSG1, ERCC1 IAPP 3329/4885PTGS1 1310/4885MMP2 1116/4885
US-20230364069-A1 METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR TGFBR2, TGFBR1, TGFB1 IAPP 190/4885PTGS1 861/4885MMP2 1215/4885
US-20230364171-A1 SENSORY MODIFIER COMPOUNDS TAS2R4, TAS2R50, TAS2R20 IAPP 242/4885PTGS1 2335/4885MMP2 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.